OIPE IAP33 SEP 08 2005 PATENT & TRADEMARK OFFICE

Form PTO-1449	Attorney's Docket No. 39766-0073 A2	Application Serial No. 09/811,123
INFORMATION DISCLOSURE STATEMENT	Applicant(s) Sharon ERICKSON, et al.	
(use several sheets if necessary)	Filing Date: March 16, 2001	Group Art Unit: 1642

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation YES	Translation NO

OTHER DOCUMENTS
(including author, title, date, pertinent pages, etc.)

Examiner Initials	Ref. No.	Title
H.S.	1.	Chari, RVJ "Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy," Advanced Drug Delivery Reviews 31:89-104 (1998)
H.S	2.	Spector et al., "Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies," Jour. of Clin. Onc. 23(11):2502-2512 (2005)

EXAMINER: Hong Sang	DATE CONSIDERED: 10/7/2005

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).